Refludan
lepirudin
Lepirudin
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
If any of the side effects gets serious, or if you notice side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
What Refludan is and what it is used for
Before you use Refludan
How to use Refludan
Possible side effects
5 How to store Refludan
6. Further information
Refludan is an antithrombotic medicine.
Medicinal product no longer authorised
Antithrombotics are medicines to prevent formation of blood clots (thrombosis).
Refludan is used for anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II and thromboembolic disease requiring injected antithrombotic medicines. HIT type II is an illness which can occur after you have received heparin containing medicines. It constitutes a certain kind of allergy towards heparin. It may result in a too low number of blood platelets and/or clots in your blood vessels (thrombosis).
This may additionally lead to deposition of clots in organs.
if you are allergic (hypersensitive) to lepirudin, to hirudins or any of the other ingredients of Refludan.
if you are pregnant or breast-feeding.
If you have a bleeding tendency, your doctor will weigh the risk of Refludan administration against its benefit. Thus, please tell your doctor if you have or have had:
Recent puncture of large vessels or organs
Anomaly of vessels or organs
Recent stroke, accident or surgery involving the brain
High blood pressure
Inflammation of the inner membrane of the heart
Recent major surgery
Recent bleeding (e.g. in brain, stomach/intestine, eye, lung)
Obvious signs of bleeding
Recent active peptic ulcer
Age > 65 years
Please inform your doctor if you suffer from reduced kidney function or liver cirrhosis (advanced disease of the liver) for he will then reduce the dosage.
You should also inform your doctor if you have ever received Refludan, hirudin or a hirudin analogue.
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.
Medicines given to break up clots or tablets to prevent clot formation (coumarins) may increase the risk of bleeding when given at the same time.
Ask your doctor or pharmacist for advice before taking any medicine. Refludan should not be administered to pregnant women or nursing mothers.
Medicinal product no longer authorised
Your doctor will determine and control the dosage and duration of your treatment with Refludan according to your clinical condition, your body weight, and certain laboratory values.
If you have the impression that the effect of Refludan is too strong or too weak, talk to your doctor or pharmacist.
Refludan, once reconstituted with an appropriate solvent, will be administered into a vein, by injection and then by infusion.
Like all medicines, Refludan can have side effects, although not everybody gets them. Very common (at least 1 in 10 people)
Bleeding
Reported bleeding events include: anaemia or drop in the haemoglobin value without obvious source of bleeding, bruising, bleeding from puncture sites, nose bleeding, blood in urine, gastrointestinal bleeding, vaginal bleeding, rectal bleeding, pulmonary haemorrhage, bleeding into chest space and around the heart following surgery, bleeding into the brain.
Severe bleeding and, in particular, intracranial bleeding may be fatal. In intensified post-marketing surveillance in HIT type II, fatal bleeding was reported in 1 % and intracranial bleeding in 0.2 % of patients. Severe bleeding may lead to decreased volume of circulating blood, low blood pressure, shock, and their clinical sequelae.
Rare (less than 1 in 1,000 people affected)
Allergic skin reactions (including rash), itching, hot flushes, fever, chills.
Anaphylactic/oid reactions including urticaria, difficulty in breathing (e.g. consisting of spasms), cough, sharp sound when breathing, build-up of water in the body and in the inner
wall of a vessel (including: face oedema, tongue oedema, throat oedema). In severe cases these may lead to shock and death.
Injection site reactions, including pain.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Keep out of the reach and sight of children.
Do not use Refludan after the expiry date which is stated on the carton and the vial after EXP. Do not store above 25C. Do not freeze.
Keep the -vial in the outer carton.
Do not use Refludan if the reconstituted solution is cloudy or contains particles. Once reconstituted Refludan is to be used immediately.
Any unused solution must be discarded appropriately.
Medicinal product no longer authorised
The active substance is lepirudin, a recombinant DNA product derived from yeast cells. The other ingredients are mannitol (E421) and sodium hydroxide for PH adjustment.
Refludan is a white powder for solution for injection or infusion supplied in a vial containing 20 mg lepirudin. Refludan is available in packs of 1 or 10 vials. Not all pack sizes may be marketed.
Celgene Europe Ltd., 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, United Kingdom.
CSL Behring GmbH, Emil-von-Behring-Straße 76, 35041 Marburg, Germany.
<------------------------------------------------------------------------------------------------------------------------------
The following information is intended for medical or healthcare professionals only:
General recommendations
Reconstitution and further dilution must be carried out under sterile conditions.
For reconstitution water for injections or sodium chloride 9 mg/ml (0.9 %) solution are to be used.
For further dilution sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solutions are suitable.
For rapid, complete reconstitution, inject 0.4 ml of diluent into the vacuum vial and shake it gently. On reconstitution a clear, colourless solution is usually obtained within less than
3 minutes.
Do not use solutions which are cloudy or contain particles.
The reconstituted solution is to be used immediately.
The preparation should be warmed to room temperature before administration.
Any unused solution must be discarded appropriately.
For injection only polypropylene syringes may be used.
Preparation of a Refludan solution with a concentration of 5 mg/ml
For intravenous. bolus injection a solution with a concentration of 5 mg/ml is needed:
Reconstitute one vial (20 mg of lepirudin) with 0.4 ml of either water for injections or sodium chloride 9 mg/ml (0.9 %) solution.
Medicinal product no longer authorised
The final concentration of 5 mg/ml is obtained by transfer into a sterile, single-use syringe (of at least 5 ml capacity) and further dilution to a total volume of 4 ml using sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solution.
The final solution is to be administered in a body weight-dependent fashion.
Preparation of a Refludan solution with a concentration of 2 mg/ml
For continuous intravenous infusion, a solution with a concentration of 2 mg/ml is needed:
Reconstitute two vials (each containing 20 mg of lepirudin) with 0.4 ml each using either water for injections or sodium chloride 9 mg/ml (0.9 %) solution.
The final concentration of 2 mg/ml is obtained by transfer of both solutions into one sterile, single-use perfusor syringe (50 ml capacity) and further dilution to a total volume of 20 ml using sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solution.
The infusion speed of the perfusor automate is to be set in a body weight-dependent fashion.
The perfusor syringe must be changed at least every 12 hours after the start of the infusion.